Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

January 16, 2020

Hayden v. Portola Pharmaceuticals, Inc. et al

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. September 20, 2022

    Portola Pharma Investors Ink $17.5M Deal Over Stock Declines

    Investors in biotechnology company Portola Pharmaceuticals Inc. have asked a San Francisco federal judge to give an initial nod to a $17.5 million deal that would end claims the company failed to acknowledge its prime drug candidate, a blood coagulant, would face stiff competition from an off-label drug used for the same purpose, hurting investors when the company revealed its struggles to sell its drug.

2 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login